Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1

Abstract Although there is considerable genetic and pathologic evidence for an association between neuregulin 1 (NRG1) dysregulation and schizophrenia, the underlying molecular and cellular mechanisms remain unclear. Mutant mice containing disruption of the transmembrane (TM) domain of the NRG1 gene constitute a heuristic model for dysregulation of NRG1-ErbB4 signaling in schizophrenia. The present study focused on hitherto uncharacterized information processing phenotypes in this mutant line. Using a mass spectrometry-based metabolomics approach, we also quantified levels of unique metabolites in brain. Across 2 different sites and protocols, Nrg1 mutants demonstrated deficits in prepulse inhibition, a measure of sensorimotor gating, that is, disrupted in schizophrenia; these deficits were partially reversed by acute treatment with second, but not first-, generation antipsychotic drugs. However, Nrg1 mutants did not show a specific deficit in latent inhibition, a measure of selective attention that is also disrupted in schizophrenia. In contrast, in a “what–where–when” object recognition memory task, Nrg1 mutants displayed sex-specific (males only) disruption of “what–when” performance, indicative of impaired temporal aspects of episodic memory. Differential metabolomic profiling revealed that these behavioral phenotypes were accompanied, most prominently, by alterations in lipid metabolism pathways. This study is the first to associate these novel physiological mechanisms, previously independently identified as being abnormal in schizophrenia, with disruption of NRG1 function. These data suggest novel mechanisms by which compromised neuregulin function from birth might lead to schizophrenia-relevant behavioral changes in adulthood.

[1]  I. McGregor,et al.  Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  C. Buechler,et al.  Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma. , 2016, Biochimica et biophysica acta.

[3]  D. Volk,et al.  Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia , 2016, Schizophrenia Research.

[4]  R. Gruetter,et al.  Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis. , 2016, Schizophrenia bulletin.

[5]  Yiyun Huang,et al.  Reduced Brain Cannabinoid Receptor Availability in Schizophrenia , 2016, Biological Psychiatry.

[6]  E. Hoxha,et al.  Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia , 2016, Translational psychiatry.

[7]  H. Nawa,et al.  Perinatal Exposure to Neuregulin-1 Results in Disinhibition of Adult Midbrain Dopaminergic Neurons: Implication in Schizophrenia Modeling , 2016, Scientific Reports.

[8]  J. Waddington,et al.  Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness , 2015, Neuroscience & Biobehavioral Reviews.

[9]  C. Chiapponi,et al.  Brain structure, cognition and negative symptoms in schizophrenia are associated with serum levels of polysialic acid-modified NCAM , 2015, Translational Psychiatry.

[10]  S. Matsuoka,et al.  Protective effects of polysialic acid on proteolytic cleavage of FGF2 and proBDNF/BDNF. , 2015, Glycobiology.

[11]  H. Kaya,et al.  Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings , 2015, Schizophrenia Research.

[12]  D. Pinault,et al.  Neuregulin 1 Expression and Electrophysiological Abnormalities in the Neuregulin 1 Transmembrane Domain Heterozygous Mutant Mouse , 2015, PloS one.

[13]  D. Henderson,et al.  Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. , 2015, The lancet. Psychiatry.

[14]  Xu-Feng Huang,et al.  Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain , 2015, Psychiatry Research.

[15]  D Lindberg,et al.  Purinergic signaling and energy homeostasis in psychiatric disorders. , 2015, Current molecular medicine.

[16]  Julie A. Wood,et al.  Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia , 2015, Schizophrenia Research.

[17]  B. Pickard,et al.  Schizophrenia biomarkers: Translating the descriptive into the diagnostic , 2015, Journal of psychopharmacology.

[18]  M. Bennett,et al.  Partial genetic deletion of neuregulin 1 modulates the effects of stress on sensorimotor gating, dendritic morphology, and HPA axis activity in adolescent mice. , 2014, Schizophrenia bulletin.

[19]  C. Turck,et al.  Lipidomics reveals dysfunctional glycosynapses in schizophrenia and the G72/G30 transgenic mouse , 2014, Schizophrenia Research.

[20]  J. Waddington,et al.  Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1 , 2014, Neuroscience.

[21]  W. Lai,et al.  Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits , 2014, Front. Behav. Neurosci..

[22]  Rita Gerardy-Schahn,et al.  Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. , 2014, Physiological reviews.

[23]  R. Landgraf,et al.  Environmental manipulations generate bidirectional shifts in both behavior and gene regulation in a crossbred mouse model of extremes in trait anxiety , 2014, Front. Behav. Neurosci..

[24]  S. Hyman Time for New Schizophrenia Rx , 2014, Science.

[25]  N. Swerdlow,et al.  Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats , 2013, Behavioural Brain Research.

[26]  J. Krauss,et al.  Hypomethylation of neuregulin in rats selectively bred for reduced sensorimotor gating , 2013, Schizophrenia Research.

[27]  M. Keshavan,et al.  Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis , 2013, Front. Cell. Neurosci..

[28]  I. McGregor,et al.  Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice , 2013, Front. Cell. Neurosci..

[29]  H. Nawa,et al.  ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease , 2013, Front. Cell. Neurosci..

[30]  W. Drevets,et al.  Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile , 2012, Scientific Reports.

[31]  Matcheri S. Keshavan,et al.  Associations between Purine Metabolites and Clinical Symptoms in Schizophrenia , 2012, PloS one.

[32]  D. Rujescu,et al.  Schizophrenia shows a unique metabolomics signature in plasma , 2012, Translational Psychiatry.

[33]  J. Waddington,et al.  Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: A putative model of gene×environment interaction , 2012, Brain, Behavior, and Immunity.

[34]  K. Newell,et al.  Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life , 2012, European Neuropsychopharmacology.

[35]  D. Blackwood,et al.  Transcriptional regulation of neurodevelopmental and metabolic pathways by NPAS3 , 2012, Molecular Psychiatry.

[36]  C. Sato,et al.  Novel Regulation of Fibroblast Growth Factor 2 (FGF2)-mediated Cell Growth by Polysialic Acid* , 2011, The Journal of Biological Chemistry.

[37]  R. Chesworth,et al.  Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit? , 2011, Behavioural Brain Research.

[38]  C. McBain,et al.  Conserved Interneuron-Specific ErbB4 Expression in Frontal Cortex of Rodents, Monkeys, and Humans: Implications for Schizophrenia , 2011, Biological Psychiatry.

[39]  Xu-Feng Huang,et al.  Antipsychotic treatment and neuregulin 1–ErbB4 signalling in schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  A. Kakita,et al.  Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia , 2011, Molecular Psychiatry.

[41]  A. Ennaceur One-trial object recognition in rats and mice: Methodological and theoretical issues , 2010, Behavioural Brain Research.

[42]  M. Ozaki,et al.  Phenotypic Characterization of Transgenic Mice Overexpressing Neuregulin-1 , 2010, PloS one.

[43]  Tilo Kircher,et al.  The effect of Neuregulin 1 on neural correlates of episodic memory encoding and retrieval , 2010, NeuroImage.

[44]  T. Karl,et al.  Cognition in transmembrane domain neuregulin 1 mutant mice , 2010, Neuroscience.

[45]  J. Waddington,et al.  Advancing a functional genomics for schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene disruption , 2010, Brain Research Bulletin.

[46]  Richard S. Ehrlichman,et al.  Mouse behavioral endophenotypes for schizophrenia , 2010, Brain Research Bulletin.

[47]  A. Buonanno,et al.  The neuregulin signaling pathway and schizophrenia: From genes to synapses and neural circuits , 2010, Brain Research Bulletin.

[48]  J. Lieberman,et al.  Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. , 2010, Trends in pharmacological sciences.

[49]  G. Rouleau,et al.  Association of NPAS3 exonic variation with schizophrenia , 2010, Schizophrenia Research.

[50]  R. Chesworth,et al.  A follow-up study: acute behavioural effects of Δ9-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice , 2010, Psychopharmacology.

[51]  H. Nawa,et al.  Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism , 2010, Journal of Neural Transmission.

[52]  J. Gogos,et al.  Cognition in mouse models of schizophrenia susceptibility genes. , 2010, Schizophrenia bulletin.

[53]  M. Rietschel,et al.  Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[54]  R. Harvey,et al.  Schizophrenia‐related endophenotypes in heterozygous neuregulin‐1 ‘knockout’ mice , 2010, The European journal of neuroscience.

[55]  Xin-Hong Zhu,et al.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons , 2009, Proceedings of the National Academy of Sciences.

[56]  I. Weiner,et al.  Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment , 2009, Behavioural Brain Research.

[57]  M. van den Buuse,et al.  Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. , 2009, The international journal of neuropsychopharmacology.

[58]  K L Evans,et al.  Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder , 2009, Molecular Psychiatry.

[59]  Q. Xing,et al.  A two-method meta-analysis of Neuregulin 1(NRG1) association and heterogeneity in schizophrenia , 2009, Schizophrenia Research.

[60]  J. Waddington,et al.  Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. , 2009, The international journal of neuropsychopharmacology.

[61]  F. Dickerson,et al.  A double-blind trial of adjunctive allopurinol for schizophrenia , 2009, Schizophrenia Research.

[62]  Claudia S. Barros,et al.  Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system , 2009, Proceedings of the National Academy of Sciences.

[63]  P. McKenna,et al.  High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. , 2008, Journal of proteome research.

[64]  Jing-ping Zhao,et al.  Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia , 2008, Neuroscience Letters.

[65]  T. Si,et al.  Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. , 2008, The international journal of neuropsychopharmacology.

[66]  L. Mei,et al.  Neuregulin 1 in neural development, synaptic plasticity and schizophrenia , 2008, Nature Reviews Neuroscience.

[67]  Laura L. Vernon,et al.  Cognitive correlates of schizophrenia signs and symptoms: III. Hallucinations and delusions , 2008, Psychiatry Research.

[68]  M. Webster,et al.  Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients , 2008, Schizophrenia Research.

[69]  L. Hong,et al.  Evidence of Missense Mutations on the Neuregulin 1 Gene Affecting Function of Prepulse Inhibition , 2008, Biological Psychiatry.

[70]  M. Munafo,et al.  Neuregulin 1 genotype and schizophrenia. , 2007, Schizophrenia bulletin.

[71]  P. Schofield,et al.  Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia , 2007, Genes, brain, and behavior.

[72]  J. Waddington,et al.  Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia risk gene neuregulin 1 , 2007, Neuroscience.

[73]  Roberto Malinow,et al.  The Neuregulin-1 Receptor ErbB4 Controls Glutamatergic Synapse Maturation and Plasticity , 2007, Neuron.

[74]  Kari Stefansson,et al.  Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function in NRG1+/− Knock-Outs Compared with Wild-Type Mice , 2007, The Journal of Neuroscience.

[75]  K. Krishnan,et al.  Metabolomic mapping of atypical antipsychotic effects in schizophrenia , 2007, Molecular Psychiatry.

[76]  P. Schofield,et al.  Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ9-tetrahydrocannabinol , 2007, Psychopharmacology.

[77]  Daniel R Weinberger,et al.  expression in the brain , 2006 .

[78]  J. P. Huston,et al.  The case for episodic memory in animals , 2006, Neuroscience & Biobehavioral Reviews.

[79]  M. Reveley,et al.  Measuring memory impairment in community-based patients with schizophrenia , 2006, British Journal of Psychiatry.

[80]  Paul J. Harrison,et al.  Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology , 2006, Biological Psychiatry.

[81]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[82]  Paul J. Harrison,et al.  Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Joseph P. Huston,et al.  Wistar rats show episodic-like memory for unique experiences , 2006, Neurobiology of Learning and Memory.

[84]  F. Lee,et al.  Neurotrophin signalling in health and disease. , 2006, Clinical science.

[85]  R. Harrington,et al.  Identification of Disease Markers in Human Cerebrospinal Fluid Using Lipidomic and Proteomic Methods , 2005, Disease markers.

[86]  Joseph P. Huston,et al.  Integrated memory for objects, places, and temporal order: Evidence for episodic-like memory in mice , 2005, Neurobiology of Learning and Memory.

[87]  Douglas W. Barrett,et al.  Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition , 2005, Neuroreport.

[88]  Michael F. Green,et al.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.

[89]  Tobias M. Fischer,et al.  Short- and Long-Range Attraction of Cortical GABAergic Interneurons by Neuregulin-1 , 2004, Neuron.

[90]  C. Byrne,et al.  Schizophrenia, the metabolic syndrome and diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[91]  R Hashimoto,et al.  Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia , 2004, Molecular Psychiatry.

[92]  H. Stefánsson,et al.  Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.

[93]  Ronan E. O'Carroll,et al.  Cognitive impairment in schizophrenia , 2000 .

[94]  Jeffrey K. Yao,et al.  Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients , 2000, Schizophrenia Research.

[95]  D. Weinberger,et al.  Cognitive deficits and the neurobiology of schizophrenia , 1995, Current Opinion in Neurobiology.

[96]  R. Quirion,et al.  Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[97]  J. Waddington,et al.  Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models. , 2014, Progress in brain research.

[98]  J. Waddington,et al.  Mutant mouse models in evaluating novel approaches to antipsychotic treatment. , 2012, Handbook of experimental pharmacology.

[99]  Sarah Tosato,et al.  Association between the neuregulin 1 gene and schizophrenia: a systematic review. , 2005, Schizophrenia bulletin.